Physician profile
Mada H Jamil
NPI 1386716280
$5,579.86
in general payments reported to CMS, 2019-2025
22 companies · $1,611 in 2025
The $1,611 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $951 · 2020: $404 · 2021: $595 · 2022: $896 · 2023: $607 · 2024: $517 · 2025: $1,611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,734.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,734.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,240.23 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $853.84 | 2019-2025 | Repatha, Krystexxa |
| Glaxosmithkline, LLC. | $593.19 | 2021-2025 | Penmenvy, Arexvy |
| Astrazeneca Pharmaceuticals LP | $574.55 | 2021-2025 | Airsupra, Breztri |
| Lilly USA, LLC | $417.63 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Regeneron Healthcare Solutions, INC. | $354.31 | 2022-2023 | Dupixent |
| Otsuka America Pharmaceutical, INC. | $253.03 | 2023 | Nuedexta, Rexulti |
| Tris Pharma INC | $242.70 | 2025 | Dyanavel Xr, Quillivant, Quillichew Er |
| Actelion Pharmaceuticals US, INC. | $144.35 | 2023-2025 | Opsumit, Uptravi |
| Pfizer INC. | $136.66 | 2019 | |
| Ironshore Pharmaceuticals INC. | $121.35 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $109.80 | 2023 | Trulance, Xifaxan |
| Agios Pharmaceuticals, INC. | $103.70 | 2025 | Pyrukynd |
| Covidien LP | $84.94 | 2019 | |
| Merck Sharp & Dohme LLC | $83.64 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bsn Medical INC | $72.37 | 2025 | |
| Genentech USA, INC. | $65.85 | 2020-2021 | |
| Exact Sciences Corporation | $42.26 | 2024-2025 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $36.56 | 2025 | |
| Abbvie INC. | $19.42 | 2025 | |
| Hologic Sales and Service, LLC | $18.42 | 2024 | Aptima |
| Janssen Pharmaceuticals, INC | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mada Jamil listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.